This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of fingolimod
MSMED_FINGOLIMOD
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
365 |
4. Check minimum number of events
Min. number of events
3
|
365 |
5. Include endpointsNone |
365 |
6. Filter based on genotype QC (FinnGen only) |
328 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of fingolimod
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 328 | 266 | 62 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.03 |
| Median age at first event (years) | 38.47 | 38.13 | 39.94 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 349
- Matched controls
- 3490
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
109
Kela drug reimbursment
Multiple sclerosis
12373.7
307.7
346
21
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
902.4
307.7
295
21
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
349
31
L04AA27
ATC
[U] fingolimod
+∞
307.7
349
*
164
Kela drug reimbursment
Fingolimod
+∞
307.7
349
*
L03AB07
ATC
interferon beta-1a; parenteral
461.7
307.7
199
10
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
58.7
307.7
270
192
353
Kela drug reimbursment
Cladribine and fingolimod
7944.7
307.7
312
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
1043.4
307.7
297
19
H46
ICD-10 Finland
Optic neuritis
124.8
283.0
146
20
L03AX13
ATC
glatiramer acetate; parenteral
472.9
201.0
183
8
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
73.6
187.8
104
20
N86
ICPC
Multiple sclerosis
439.0
177.6
164
7
L04AE01
ATC
fingolimod; oral
+∞
156.3
138
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
45.6
152.6
94
28
Z01.0
ICD-10 Finland
Examination of eyes and vision
15.1
152.4
208
310
M03BX01
ATC
baclofen; systemic
34.8
136.2
91
35
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
44.8
130.4
80
23
L03AB08
ATC
interferon beta-1b; parenteral
1595.2
120.2
110
*
ZX120
NOMESCO Finland
Intravenous
14.2
109.4
119
123
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
11.2
101.0
136
188
N04BB01
ATC
amantadine; oral
157.2
99.2
101
9
XKD00
NOMESCO Finland
Uroflowmetry
18.1
98.2
87
63
G04BD12
ATC
mirabegron; oral
14.1
97.0
102
99
XCK00
NOMESCO Finland
Perimetry
17.9
92.7
82
59
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
19.6
89.9
75
48
TAB00
NOMESCO Finland
Lumbar puncture
13.2
87.5
95
96
XKD06
NOMESCO Finland
Physiologic investigation of micturition
30.7
86.7
59
23
XCW99
NOMESCO Finland
Other investigative procedure of eye
11.6
84.9
103
122
H02AB04
ATC
methylprednisolone; systemic
8.4
79.8
138
251
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
17.0
75.3
67
48
XA800
NOMESCO Finland
Neuropsychological investigation
12.4
74.7
83
86
G04BD08
ATC
solifenacin; oral
15.6
62.9
58
44
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
10.4
61.2
76
91
2AB04, ,
NOMESCO Finland
147.2
59.0
61
5
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
21.0
58.8
46
25
L04AA31
ATC
[U] teriflunomide
221.5
55.8
56
*
XKC03
NOMESCO Finland
Water cystometry
18.1
54.8
46
29
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
10.8
52.0
61
67
UKC02
NOMESCO Finland
Cystoscopy
7.6
49.7
81
133
4AA23, ,
NOMESCO Finland
524.5
47.5
46
*
L04AX07
ATC
dimethyl fumarate; oral
67.6
45.8
52
9
G04BD09
ATC
trospium; oral
82.9
45.4
50
7
H53.2
ICD-10 Finland
Diplopia
14.3
45.1
43
34
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
7.6
44.6
71
113
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
15.4
44.1
40
29
R1250
NOMESCO Finland
Evaluation of functional capability
13.5
43.6
43
36
N06BA07
ATC
modafinil; oral
75.3
41.2
46
7
N07XX09
ATC
[U] dimethyl fumarate
83.4
40.0
44
6
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
218.8
38.6
39
*
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
13.7
38.1
37
30
G04BD07
ATC
tolterodine; oral
13.3
35.5
35
29
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.5
33.9
76
168
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
367.3
33.5
33
*
N05CF01
ATC
zopiclone; oral
3.9
33.4
159
623
L04AG12
ATC
ofatumumab; parenteral
181.6
32.3
33
*
N03AX12
ATC
[U] gabapentin; oral
4.4
32.0
103
305
Z3226
NOMESCO Finland
Physiotherapist
4.3
31.9
107
327
R35
ICD-10 Finland
Polyuria
7.0
30.5
50
81
C10AC01
ATC
colestyramine; oral
10.1
29.6
35
38
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
113.1
29.2
31
*
TKC22
NOMESCO Finland
Catheterisation instruction
45.4
27.3
33
8
SPAT1229
SPAT
Assessment of need for aid
8.6
26.9
36
46
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
11.2
26.6
29
28
Z3229
NOMESCO Finland
Other healthcare associate professional
6.1
26.1
49
91
N03AE01
ATC
clonazepam; systemic
6.2
25.4
47
86
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.6
25.3
53
109
R20.2
ICD-10 Finland
Paraesthesia of skin
4.4
23.8
69
186
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
67.1
22.2
25
*
N03AX16
ATC
[U] pregabalin
3.3
22.1
113
445
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
64.2
21.2
24
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
222.7
20.8
21
*
Z3231
NOMESCO Finland
Registered nurse
3.0
20.1
130
582
N39.4
ICD-10 Finland
Other specified urinary incontinence
5.2
20.0
44
94
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
20.0
19
*
N02BF01
ATC
gabapentin; oral
3.9
19.9
67
200
L04AA40
ATC
cladribine; oral
77.8
19.9
22
*
XCK10
NOMESCO Finland
Photography of fundus of eye
4.9
19.8
47
107
Z2445
NOMESCO Finland
Psychologist
5.0
19.5
45
100
L28
ICPC
Limited function/disability (L)
3.8
19.2
68
210
R4110
NOMESCO Finland
Physiotherapy
2.9
19.2
123
546
SPAT1215
SPAT
Assessment of need for medical rehabilitation
6.5
18.9
32
53
J01EA01
ATC
trimethoprim; systemic
2.9
18.8
131
607
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
3.0
18.7
112
478
G04CA01
ATC
alfuzosin; oral
6.4
18.6
32
54
R5110, ,
SPAT
5.2
18.3
40
85
R4120
NOMESCO Finland
Occupational therapy
4.5
18.2
48
119
G04BD04
ATC
oxybutynin; oral, transdermal
6.4
18.1
31
52
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
+∞
17.9
17
*
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
39.0
17.8
22
6
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.4
17.7
76
266
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.1
17.3
27
41
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
27.2
17.1
23
9
XKD03
NOMESCO Finland
Urethral pressure profilometry
20.6
17.1
25
13
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
15.1
17.1
28
20
RF120, ,
NOMESCO Finland
31.8
16.3
21
7
A02BC02
ATC
pantoprazole; systemic
2.8
16.3
260
1775
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
27.8
15.8
21
8
L03AB13
ATC
peginterferon beta-1a; parenteral
167.2
15.6
16
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.3
15.2
66
231
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
33.4
15.0
19
6
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.5
14.7
150
819
A28
ICPC
Limited function/disability NOS
4.0
14.5
44
121
G04CA02
ATC
tamsulosin; oral
4.4
14.4
38
94
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.2
14.2
40
104
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
7.0
14.2
22
33
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.6
14.2
28
54
XCD10
NOMESCO Finland
Electrophysiological examination of eye
11.1
14.0
26
25
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
145.4
13.5
14
*
G04BD11
ATC
fesoterodine; oral
19.2
13.5
20
11
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.6
13.4
33
77
RF420, ,
NOMESCO Finland
20.0
13.1
19
10
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
33.4
12.7
16
5
N06AX16
ATC
venlafaxine; oral
2.6
12.6
93
432
L01BB04
ATC
cladribine; systemic
+∞
12.6
12
*
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
27.8
12.2
16
6
RF410, ,
NOMESCO Finland
22.2
12.1
17
8
R4150
NOMESCO Finland
Neuropsychological rehabilitation
12.3
12.0
21
18
N30.9
ICD-10 Finland
Cystitis, unspecified
3.6
11.2
39
118
N30.0
ICD-10 Finland
Acute cystitis
2.5
11.2
88
419
N29
ICPC
Neurological sympt/complt other
9.3
10.9
22
25
Z50.1
ICD-10 Finland
Other physical therapy
5.2
10.9
23
47
H02AB06
ATC
prednisolone; systemic
2.1
10.6
174
1116
U13
ICPC
Bladder symptom/complaint other
8.0
10.1
22
29
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
41.3
10.0
12
*
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.2
10.0
27
68
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
26.9
9.9
13
5
A06AD11
ATC
lactulose; oral
3.2
9.5
39
131
R33
ICD-10 Finland
Retention of urine
4.9
9.4
21
45
WW400
NOMESCO Finland
Plasmaferesis
+∞
9.4
9
*
A06AC01
ATC
ispaghula (psylla seeds); oral
2.2
9.3
91
474
R15
ICD-10 Finland
Faecal incontinence
9.4
9.1
18
20
J05AB01
ATC
aciclovir; systemic
2.1
8.9
104
580
Z2446
NOMESCO Finland
Social worker
3.1
8.9
38
131
U01
ICPC
Dysuria/painful urination
3.0
8.8
40
143
H47.2
ICD-10 Finland
Optic atrophy
51.3
8.7
10
*
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.0
8.7
25
66
OAB50, ,
SPAT
3.4
8.6
32
101
NA1DG
NOMESCO Finland
Cervical spine very extensive MRI examination with high intensity magnet
28.3
8.5
11
*
G51.0
ICD-10 Finland
Bell palsy
7.0
8.5
20
30
359
Kela drug reimbursment
Mirabegroni
92.2
8.4
9
*
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
13.2
8.4
14
11
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
+∞
8.4
8
*
RS340, ,
NOMESCO Finland
+∞
8.4
8
*
H53.1
ICD-10 Finland
Subjective visual disturbances
2.9
8.4
40
147
TKC20
NOMESCO Finland
Catheterisation of bladder
4.0
7.9
23
61
J01CA08
ATC
pivmecillinam; oral
1.9
7.9
188
1330
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.5
7.8
27
81
R42
ICD-10 Finland
Dizziness and giddiness
2.2
7.7
71
358
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
7.7
75
387
N03AF01
ATC
carbamazepine; oral, rectal
3.8
7.6
23
63
G04BE03
ATC
sildenafil; oral
81.8
7.4
8
*
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
13.8
7.4
12
9
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
7.3
7
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
7.3
7
*
N04BD01
ATC
selegiline; oral
16.2
7.3
11
7
U02
ICPC
Urinary frequency/urgency
2.3
7.3
57
268
XF400
NOMESCO Finland
ECG with 12 standard connections
2.6
7.0
42
174
J05AB11
ATC
valaciclovir; oral
2.2
7.0
69
357
N28
ICPC
Limited function/disability (N)
11.2
6.8
12
11
RS222, ,
NOMESCO Finland
11.2
6.8
12
11
J01AA02
ATC
doxycycline; systemic
2.0
6.8
273
2235
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
40.9
6.8
8
*
RS221, ,
NOMESCO Finland
8.1
6.7
14
18
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
71.1
6.4
7
*
SPAT1325
SPAT
Vaccination
1.9
6.4
95
569
SPAT1216
SPAT
Assessment of functional ability
2.7
6.3
34
133
4AA36, ,
NOMESCO Finland
+∞
6.3
6
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
27.2
6.3
8
*
SPAT1295
SPAT
Other function in accordance with physical therapy nomenclature
3.9
6.2
18
48
N99
ICPC
Neurological disease other
10.3
6.1
11
11
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.1
117
760
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
160
69
41.97
236.28
1.3
1.1
—
—
—
0
0
172
232
13.65
133.51
5.0
2.1
9.03
10.35
g/l
5.95
167
219
105
9
166.07
103.77
3.0
2.8
—
—
—
0
0
55
19
34.18
84.02
2.5
2.8
—
—
—
0
0
324
1488
17.44
70.58
22.0
5.8
65.41
56.53
%
44.83
324
1437
339
1762
33.25
61.42
23.1
9.1
3.37
3.92
e9/l
10.36
334
1554
228
834
6.00
59.97
7.5
2.8
—
—
—
0
0
55
42
15.36
59.31
1.2
1.1
—
—
—
0
0
195
640
5.64
57.86
5.9
2.4
0.10
0.23
e6/l
1.52
170
434
44
23
21.75
57.16
1.3
1.1
1878.84
1567.74
miu/ml
0.66
44
23
45
26
19.72
55.87
3.7
2.0
434.06
491.43
e6/l
0.44
34
21
283
1375
6.60
49.71
8.0
5.5
9.68
9.74
umol/l
0.05
277
1316
75
151
6.05
37.17
1.6
1.5
—
—
—
0
0
42
8
59.41
36.31
1.2
1.0
—
—
—
0
0
117
379
4.14
32.20
5.3
2.2
0.84
0.75
e6/l
0.09
66
171
303
1890
5.58
30.89
11.6
3.8
45.33
904.93
e6/l
—
6
15
274
1624
4.20
29.06
8.3
3.1
0.00
0.00
estimate
-0.00
81
311
270
1597
4.05
28.42
8.3
3.1
0.00
0.00
estimate
0.50
80
326
272
1618
4.09
28.36
8.4
3.1
0.00
8.97
estimate
0.80
83
325
107
359
3.86
27.54
5.5
2.3
6.31
4.07
e6/l
0.40
53
153
241
1377
3.42
25.62
2.8
2.5
97.76
72.89
nmol/l
23.69
234
1320
22
5
46.73
18.46
1.1
1.2
—
—
—
0
0
88
335
3.18
17.84
2.8
2.1
69.29
5656.72
u/l
3.04
21
143
20
6
35.22
15.91
1.8
3.7
1.41
1.69
ratio
—
20
6
149
809
2.47
14.79
10.8
3.2
0.00
0.01
estimate
1.08
80
318
33
78
4.57
13.22
1.2
1.7
12.32
13.30
e6/l
0.04
25
57
33
79
4.51
13.01
1.4
1.7
2.31
122.90
e6/l
0.97
26
60
24
23
11.12
12.96
1.0
1.0
—
—
—
0
0
194
1246
2.25
12.41
9.2
2.8
0.01
0.03
estimate
0.40
72
273
162
976
2.23
12.02
8.0
2.4
0.00
0.03
estimate
1.34
76
265
26
57
4.85
11.38
1.6
2.2
3.24
3.04
index
0.05
17
30
21
39
5.67
11.01
1.0
1.1
—
—
—
0
0
21
22
10.08
10.91
1.3
1.1
1.04
0.53
ratio
2.92
13
11
23
29
8.41
10.77
1.1
1.1
54.75
33.13
mg/l
1.28
16
24
20
39
5.38
9.96
1.0
1.1
—
—
—
0
0
238
2869
0.46
9.48
3.1
3.4
1.22
1.23
mmol/l
0.05
228
2762
19
37
5.37
9.47
1.0
1.1
—
—
—
0
0
272
2131
2.25
9.12
6.7
7.0
74.43
72.59
u/l
0.37
262
2034
262
3037
0.45
8.81
3.4
4.0
1.51
1.47
mmol/l
0.77
245
2945
264
3043
0.46
8.37
3.5
4.0
4.91
4.81
mmol/l
1.06
248
2959
269
3060
0.47
7.37
3.6
4.2
2.97
2.90
mmol/l
0.78
249
2969
325
2902
2.74
5.75
14.2
8.8
99.86
95.02
ml/min/173m2
6.47
308
2614
50
252
2.15
5.37
1.3
1.3
—
22.69
—
0
18
61
337
1.98
5.12
1.6
1.8
—
—
—
0
0
336
3094
3.31
4.79
16.2
10.7
14.60
18.36
mg/l
2.00
267
2451
14
30
4.82
4.73
1.1
1.7
—
—
—
0
0
192
1517
1.59
4.35
3.4
4.0
5.91
6.23
mmol/l
2.20
183
1384
341
3222
3.54
4.33
19.1
11.8
67.89
68.41
umol/l
0.08
341
3192
8
9
9.06
4.30
1.1
2.0
—
—
—
0
0
44
231
2.04
4.25
1.5
1.7
—
—
—
0
0
251
2815
0.61
3.86
3.1
3.7
5.51
5.60
mmol/l
0.96
229
2689
321
2941
2.14
3.78
11.6
10.0
3.91
3.90
mmol/l
0.10
315
2873
8
13
6.27
3.52
1.1
3.7
1.00
0.85
index
—
8
13
33
597
0.51
3.50
1.4
1.9
3.01
3.37
ratio
2.07
27
442
24
484
0.46
3.48
1.4
1.7
3.65
3.45
mmol/l
0.47
19
330
276
2435
1.64
3.46
6.4
3.2
53.98
34.73
u/l
5.45
270
2376
319
2936
2.01
3.38
11.5
10.0
139.89
139.60
mmol/l
2.07
314
2882
8
15
5.43
3.21
1.1
1.2
—
—
—
0
0
40
226
1.87
3.15
1.5
1.8
—
—
—
0
0
39
219
1.88
3.13
1.2
1.4
174.43
274.95
miu/ml
1.18
14
110
96
702
1.51
2.83
8.7
3.0
1.02
1.02
kg/l
0.01
76
453
133
1050
1.43
2.62
4.7
4.4
38.38
37.79
g/l
0.87
124
1001
248
2721
0.69
2.39
3.9
4.4
35.16
36.99
mmol/mol
4.54
233
2645
264
2864
0.68
2.39
32.8
13.7
333.36
332.98
g/l
0.32
264
2850
140
1145
1.37
2.16
5.6
5.9
1.21
1.21
mmol/l
0.05
117
1005
17
321
0.51
2.06
1.2
1.5
—
—
—
0
0
47
676
0.65
2.05
1.3
1.3
2.15
6.05
u/ml
1.27
17
283
30
476
0.60
2.00
1.2
1.6
1008.43
1004.35
mu/l
0.01
24
380
6
16
3.80
1.94
1.0
1.4
—
—
—
0
0
12
249
0.46
1.91
1.0
1.1
0.90
0.89
g/l
0.08
12
249
14
272
0.49
1.86
1.1
1.5
1.75
1.16
ratio
—
6
168
12
246
0.47
1.85
1.0
1.1
1.59
1.57
g/l
0.08
12
246
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
17
3.57
1.84
1.0
1.2
—
—
—
0
0
14
270
0.50
1.82
1.1
1.4
—
—
—
0
0
15
272
0.53
1.62
1.1
1.5
1.05
1.21
ratio
—
6
168
15
272
0.53
1.62
1.1
1.5
0.94
0.96
ratio
—
6
168
166
1884
0.77
1.60
3.0
3.3
77.60
72.00
ug/l
0.17
156
1821
9
184
0.48
1.55
1.6
1.8
—
—
—
0
0
17
94
1.85
1.50
4.5
2.0
1.02
1.02
ratio
0.16
12
86
118
989
1.29
1.44
5.2
5.2
1.21
1.21
mmol/l
0.46
111
934
0
40
0.00
1.33
0.0
1.6
—
—
—
0
0
6
134
0.44
1.30
7.0
2.7
4.83
5.03
kpa
—
6
128
112
943
1.28
1.30
1.8
1.6
—
—
—
0
0
58
739
0.74
1.27
1.3
1.3
9.18
21.19
iu/ml
3.32
13
211
6
25
2.42
1.25
1.0
1.4
—
—
—
0
0
16
93
1.76
1.23
1.8
2.0
—
—
—
0
0
57
722
0.75
1.20
1.9
2.0
1.90
2.65
mg/l
4.76
50
646
106
1239
0.79
1.20
1.5
1.8
1.34
1.42
mmol/l
0.52
83
1141
0
34
0.00
1.16
0.0
2.4
—
7.84
—
0
34
5
20
2.52
1.15
1.0
1.1
—
—
—
0
0
5
113
0.43
1.14
7.4
2.6
1.26
0.62
mmol/l
—
5
71
55
430
1.33
1.10
2.5
2.6
437.38
200.67
ng/l
0.24
13
202
69
842
0.77
1.10
1.9
2.0
—
—
—
0
0
8
41
1.97
1.09
1.3
1.3
—
—
—
0
0
7
33
2.14
1.06
1.3
1.5
—
—
—
0
0
77
922
0.79
1.05
2.0
2.1
—
—
—
0
0
124
1409
0.81
1.05
2.5
2.6
—
—
estimate
—
0
0
23
155
1.52
1.04
1.5
1.6
—
—
—
0
0
31
223
1.43
1.03
1.8
1.6
—
—
—
0
0
16
99
1.65
1.02
1.5
1.7
—
—
—
0
0
11
61
1.83
0.99
1.3
3.8
—
459.00
—
0
6
0
30
0.00
0.97
0.0
1.0
—
1.08
—
0
25
0
30
0.00
0.97
0.0
1.1
—
—
—
0
0
14
87
1.63
0.89
1.8
1.9
—
—
—
0
0
10
56
1.81
0.88
1.2
1.4
—
—
—
0
0
50
615
0.78
0.85
7.9
4.1
2.17
8.58
mg/mmol
3.77
29
405
6
31
1.95
0.85
1.0
1.4
—
—
—
0
0
37
472
0.76
0.83
1.8
2.0
—
—
—
0
0
33
425
0.75
0.80
1.7
2.1
2.41
2.39
mmol/l
0.31
26
380
0
25
0.00
0.79
0.0
1.3
—
—
—
0
0
32
244
1.34
0.79
2.7
6.1
105.72
104.80
mmol/l
0.72
32
244
263
2747
0.83
0.78
3.7
4.0
—
—
—
0
0
10
160
0.61
0.75
1.3
1.6
46.89
54.92
ug/l
—
10
160
12
183
0.64
0.74
1.1
2.0
—
—
—
0
0
7
39
1.81
0.73
1.0
1.6
—
—
—
0
0
19
135
1.43
0.70
3.9
2.2
14.30
4.48
iu/l
—
10
60
7
119
0.58
0.69
1.4
1.4
34.83
87.19
pmol/l
—
7
113
16
223
0.70
0.65
1.3
1.6
—
—
—
0
0
8
49
1.65
0.62
1.0
1.1
—
—
—
0
0
49
579
0.82
0.60
1.9
2.1
—
—
—
0
0
0
21
0.00
0.60
0.0
1.0
—
95.69
—
0
16
57
662
0.83
0.59
1.6
1.5
20.50
20.51
nmol/l
0.00
52
609
8
54
1.49
0.57
1.3
1.4
—
—
—
0
0
8
54
1.49
0.57
1.4
1.6
—
—
—
0
0
20
153
1.33
0.51
1.2
1.2
—
—
—
0
0
7
46
1.53
0.48
1.1
1.2
—
—
—
0
0
5
84
0.59
0.46
1.0
1.2
—
—
—
0
0
5
31
1.62
0.43
1.0
1.2
—
—
—
0
0
5
33
1.52
0.41
1.4
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.8
—
3.64
—
0
17
14
182
0.76
0.40
1.3
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.7
—
—
—
0
0
0
18
0.00
0.40
0.0
1.6
—
—
—
0
0
0
18
0.00
0.40
0.0
2.5
—
813.50
—
0
18
47
533
0.86
0.38
1.7
1.7
1.30
1.35
%
0.32
42
498
5
36
1.39
0.38
1.8
1.6
—
—
—
0
0
9
67
1.35
0.38
1.2
1.5
—
—
—
0
0
5
37
1.36
0.37
1.2
1.4
—
—
—
0
0
14
179
0.77
0.36
1.5
1.3
10.81
10.67
u/l
0.02
14
147
35
302
1.18
0.35
1.5
1.6
1089.29
1130.31
nmol/l
0.11
27
247
6
43
1.40
0.35
1.2
1.2
—
—
—
0
0
6
43
1.40
0.35
1.2
1.2
—
—
—
0
0
6
44
1.37
0.34
12.0
2.0
10.10
5.82
pmol/l
—
6
44
25
213
1.19
0.30
2.2
2.3
13.87
13.55
nmol/l
0.08
25
205
299
2937
1.13
0.30
7.2
5.6
1.56
1.68
mu/l
1.20
282
2858
88
821
1.10
0.28
3.0
2.4
10.78
19.18
ng/l
1.33
36
323
9
117
0.76
0.28
1.1
1.4
—
—
—
0
0
9
116
0.77
0.28
1.3
1.2
1.43
2.68
ug/l
—
9
105
25
216
1.17
0.26
5.7
4.8
—
—
—
0
0
5
72
0.69
0.26
1.0
1.9
—
—
—
0
0
34
381
0.88
0.25
2.0
2.4
109.37
339.96
ng/l
2.59
26
300
9
76
1.19
0.25
1.0
1.3
—
1.20
—
0
7
10
125
0.79
0.23
1.5
1.6
—
—
—
0
0
89
941
0.93
0.22
1.4
1.3
0.68
1.96
u/ml
1.24
23
275
5
41
1.22
0.22
1.4
2.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.9
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
25
223
1.13
0.18
1.0
1.1
—
—
—
0
0
102
1065
0.94
0.18
1.6
1.7
—
—
—
0
0
7
59
1.19
0.18
1.4
1.5
82.14
140.64
ug/l
—
7
54
13
110
1.19
0.17
1.0
1.3
—
13.87
—
0
23
13
110
1.19
0.17
1.0
1.2
—
2.07
—
0
9
19
215
0.88
0.17
1.2
1.5
—
—
—
0
0
6
79
0.76
0.15
1.2
1.3
—
—
—
0
0
6
79
0.76
0.15
1.0
1.3
—
—
—
0
0
93
892
1.06
0.15
2.2
3.0
2.33
2.34
mmol/l
0.46
87
839
219
2231
0.95
0.15
3.1
3.7
8.14
8.08
mm/h
0.03
211
2136
76
726
1.06
0.14
1.7
1.7
0.56
0.77
mg/l
0.75
51
542
53
500
1.07
0.14
1.5
1.5
480.84
58209369.45
pmol/l
1.05
44
469
9
108
0.83
0.13
3.6
9.2
0.87
0.64
%
—
9
108
9
110
0.81
0.13
3.6
9.1
2.00
1.37
%
—
9
110
5
45
1.11
0.10
1.2
1.7
5.68
7.76
mmol/l
—
5
45
24
257
0.93
0.09
3.5
3.3
30.39
30.96
%
0.09
18
204
5
61
0.82
0.08
1.0
1.9
2.28
2.73
g/l
—
5
61
5
61
0.82
0.08
1.0
1.9
5.80
6.79
g/l
—
5
61
5
61
0.82
0.08
1.0
1.9
4.20
4.43
g/l
—
5
61
5
61
0.82
0.08
1.0
1.9
2.80
3.65
g/l
—
5
61
7
64
1.10
0.08
1.3
1.5
—
—
—
0
0
19
205
0.92
0.08
1.5
1.4
—
—
—
0
0
18
194
0.92
0.07
1.2
1.5
0.39
0.32
mg/l
—
7
81
9
86
1.05
0.07
1.1
1.2
—
—
—
0
0
9
88
1.02
0.07
1.1
1.2
—
—
—
0
0
106
1081
0.97
0.06
1.7
1.9
103.40
96.57
pmol/l
0.60
56
623
22
207
1.07
0.06
3.2
2.6
—
—
—
0
0
10
90
1.11
0.05
1.6
2.1
0.65
0.65
%
—
10
90
17
181
0.94
0.05
3.1
7.7
-0.06
0.52
mmol/l
—
10
145
35
363
0.96
0.05
1.5
1.3
108.44
146.17
u/ml
0.53
18
167
70
687
1.02
0.03
1.9
1.9
—
—
—
0
0
259
2579
1.02
0.02
6.2
4.8
14.79
14.21
pmol/l
3.51
245
2485
18
187
0.96
0.01
2.3
2.0
94.64
85.12
ml/min/173m2
0.41
11
80
10
106
0.94
0.01
2.0
2.5
24.40
23.95
mmol/l
—
10
106
18
174
1.04
0.00
1.8
3.1
5.89
5.72
kpa
0.46
18
169
21
208
1.01
0.00
1.9
2.6
0.25
0.23
g/l
0.55
21
199
13
129
1.01
0.00
1.2
1.6
1.06
1.20
g/l
1.65
13
123
15
154
0.97
0.00
1.7
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
1.20
—
0
6
0
7
0.00
-0.00
0.0
3.7
—
12.67
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
0.04
—
0
5
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.7
—
7.12
—
0
9
5
49
1.02
-0.00
1.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.7
—
4.31
—
0
7
0
6
0.00
-0.00
0.0
1.0
—
479.67
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
14.20
—
0
9
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.01
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_FINGOLIMOD – Use of fingolimod
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).